Davis Polk advised underwriters represented by BNP Paribas Securities Corp., Deutsche Bank Securities Inc., J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC in connection with the offering of $6.5 billion aggregate principal amount of notes issued by Merck & Co., Inc. The notes were offered in six tranches, two floating-rate tranches maturing in 2016 and 2018 and four fixed-rate tranches maturing in 2016, 2018, 2023 and 2043.
Merck is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures.
The Davis Polk corporate team included partner Alan Dean, associates Ryan G. Mitteness and Kavita Paw and law clerk Ferrell Maguire. The tax team included partner Po Sit and associate Juelle Gomes. The environmental team included counsel Loyti Cheng and associate Kevin J. Klesh. Associate Bruce Rose-Innes provided intellectual property advice. Sorina Delia Lazar was the legal assistant on the transaction. All members of the Davis Polk team are based in the New York office.
